Nephrogenic systemic fibrosis: Possible mechanisms and imaging management strategies

Journal of Magnetic Resonance Imaging

Volumn 28, Issue 4, 2008, Pages 797-804

  Dawson, Peter ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; CYTOKINE; ERYTHROPOIETIN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; TRANSFORMING GROWTH FACTOR BETA;

CHEMICAL STRUCTURE; CLINICAL FEATURE; COMORBIDITY; DRUG MECHANISM; DRUG SAFETY; FIBROSIS; HEMODIALYSIS; HUMAN; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 53549114195     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21521     Document Type: Review

References (64)

1. Dawson P, Blomley MJK. The gadolinium chelate MR contrast agents. Clin Radiol 1994;49:439-442.
2. Dawson P. Gadolinium chelates: chemistry. In: Dawson P, Cosgrove DC, Grainger RG, editors. Textbook of contrast media. London: Taylor and Francis: 1999. p 291-296.
3. Weinmann H-J. Gadolinium chelates: physico-chemical properties, formulation and toxicology. In: Dawson P, Cosgrove DC, Grainger RG, editors. Textbook of contrast media. London: Taylor and Francis; 1999. p 297-318.
4. Niendorf HP, Kallend D. Gadolinium chelates: adverse reactions. In: Dawson P, Cosgrove DC, Grainger RG, editors. Textbook of contrast media. London: Taylor and Francis; 1999. p 323-332.
5. Bonnemain B. The superparamagnetic iron oxides. In: Dawson P, Cosgrove DC, Grainger RG, editors. Textbook of contrast media. London: Taylor and Francis; 1999. p 373-378.
6. Weinmann H-J, Brasch RC, Press WR. Characteristics of Gd DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984;142:619-624.
7. Dawson P. Pharmacokinetics of the lanthanide chelates. In: Dawson P, Cosgrove DC, Grainger RG, editors. Textbook of contrast media. London: Taylor and Francis; 1999. p 319-321.
8. Weinmann H-J, Press WR, Gries H. Tolerance of extracellular contrast agents for magnetic resonance imaging. Invest Radiol 1990;25:S49-S50.
9. Shellock FG, Kanal E. Safety of magnetic resonance contrast agents. J Magn Reson Imaging 1998;10:477-484.
10. Thomsen HS. Gadolinium contrast media for radiographic examinations. In: Baert AL, Sartor K, editors. Contrast media; safety issues and ESUR guidelines. Berlin: Springer; 2006. p 115-120.
11. Albrecht T, Dawson P. GdDTPA as X ray contrast medium in clinical studies. Br J Radiol 2000;73:878-882.
12. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal dialysis patients. Lancet 2000;356:1000-1001.
13. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006;8:151-1571.
14. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903-906.
15. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
16. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006;16:2619-2621.
17. Marckmann P, Skov L, Rossen K, et al. Suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
18. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? Magn Reson Mater Phys 2007;20:57-62.
19. Pedersen M. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;25:881-883.
20. Lin S-P. Brown JJ. MR contrast agents: physical and pharmacological basics. J Magn Reson Imaging 2007;25:884-899.
21. Thomsen HS, Morcos S, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 2006;61:905-906.
22. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
23. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
24. Sadowski EA, Bennett LK, Chan MR, Wentland AL, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-157.
25. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586-592.
26. Cowper SE. International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR). Nephrogenic fibrosing dermopathy. NFD/NSF website: 2001-2008. Available at: www.icnfdr.org. Last accessed: March 18, 2008.
27. Kimura J, Ishiguchi T, Matsuda J, Ohno R, et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med 2005;23:322-326.
28. Idée JM, Port M, Schaefer M, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-576.
29. Durbin PW. Metabolism of the lanthanides in the rat. Proc Soc Exp Biol 1956;91:78-81.
30. Stoffer CH. Histopathological effects of rare earths administered intraperitoneally to rats. AMA Arch Ind Health 1959;20:414.
31. Haley TJ. Pharmacology and toxicity of the rare earth elements. J Pharm Sci 1965;54:663.
32. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003;25:358.
33. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006;8:145-150.
34. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660-2666.
35. Leiner T. Presentation at the 16th Annual Meeting of ISMRM, Toronto, Ontario, Canada, May 6, 2008.
36. Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 2004;140:1401.
37. Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003;48:55-60.
38. Vogler H, Platzek I, Schumann-Giampieri G, et al. Preclinical evaluation of gadobutrol: a new, neutral, extra-cellular contrast agent for magnetic resonance imaging. Eur J Radiol 1995;21:1-10.
39. Solomon I. Relaxation processes in a system of two spins. Phys Rev 1955;99:559-565.
40. Bloembergen N. Proton relaxation times in paramagnetic solutions. J Chem Phys 1957;27:572-573.
41. Desreux JF, Gilsoul D. Chemical synthesis of paramagnetic complexes. In: Thomsen HS, Muller RN, Mattrey RF, editors. Trends in contrast media. Heidelberg: Springer Verlag; 1999. p 161-169.
42. Greenen RWF, Krestin GP. Non-tissue specific extracellular contrast media. In: Thomsen HS, editor. Contrast media: safety issues and ESUR guidelines. Berlin: Springer; 2006. p 107-114.
43. Kircheim MA, Runge VM. Contrast agents for magnetic resonance imaging. Safety update. Top Magn Reson Imaging 2003;14:426-435.
44. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8:467-481.
45. Tweedle MF, Haga JJ, Kumar K, Chang CA. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991;9:409-415.
46. Broan CJ, Cox JPL, Craig AS, et al. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-Ray molecular structure of the indium and gallium complexes of 1,4,7- triazacyclononane-1,4,7-triacetic acid. J Chem Soc Perkin Trans 1991;2:87-99.
47. Parker D, Pulukkody KP, Norman TJ, Harrison A, Royle L, Walker CA. Stable anionic, neutral and cationic complexes of gadolinium with functionalised amino-phosphinic acid macrocyclic ligands. J Chem Soc Chem Commun 1992:1441-1443.
48. Harrison A, Walker CA, Pereira KA, Parker D, et al. Hepatobiliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphine and carboxylic acids. Magn Reson Imaging 1993;11:761-770.
49. Pulukkody KP, Norman TJ, Parker D, Royle L, Broan C. Synthesis of charged and uncharged complexes of gadolinium and Yttrium with cyclic polyazaphosphinic acid ligands for in vivo applications. J Chem Soc Perkin Trans 1993;2:605-612.
50. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPABMA) (Omniscan) versus Gd (HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-278.
51. Bellin FM, Vasile M, Morel-Pracetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol 2003;13:2688-2698.
52. Vorobiov M, Basok A, Tovbin D, et al. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol Dial Transplant 2003;18:884-887.
53. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007;7:130-137.
54. Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents. Medicines and Healthcare Products Regulatory Agency, United Kingdom; 2007. Available at: http://www.mhra.gov.uk/home/idcplg?ldcService= SS_GET_PAGE&useSecondary=false&ssDocName=CON2030229&ssTargetNodeld= 221. Last accessed: June 19, 2008.
55. Committee for Medicinal Products for Human Use CHMP. Committee of The European Medicines Agency (EMEA); 2004. Available at: http://www.emea.europa.eu/ pdfs/human/press/pus/4974107en.pdf. Last accessed: July 9, 2008.
56. Information on Gadolinium-Containing Contrast Agents. Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA); 2007. Available at: http://www.fda.gov/cder/drug/infopage/gcca/default.htm. Last accessed: June 19, 2008.
57. Updated ACR Screening Recommendations on Gadolinium-Based MR Contrast Agents, Renal Disease Patients, and Nephrogenic Systemic Fibrosis (NSF). American College of Radiology (ACR); 2008. Available at: www.acr.org/ SecondaryMainMenuCategories/quality_safety/MRSafety/recommendations_gadolinium- based.aspx. Last accessed: June 19, 2008.
58. Nephrogenic Fibrosis. European Society of Urogenital Radiology (ESUR); 2008. Available at: http://www.esur.org/Nephrogenic_Fibrosis.39.0.html. Last accessed: June 19, 2008.
59. International Society for Magnetic Resonance in Medicine (ISMRM). Home page; 2008. Available at: http://www.ismrm.org. Last accessed: June 19, 2008.
60. European Society for Magnetic Resonance in Medicine and Biology (ESMRMB). Home page; 2008. Available at: http://www.esmrmb.org. Last accessed: June 19, 2008.
61. Haustein J, Schumann-Giampieri G. Elimination of Gd DTPA by means of haemodialysis. Eur Radiol 1990;11:27-29.
62. Dorsam J, Knopp M, Schad L, et al. Elimination of Gd DTPA by peritoneal dialysis. Nephrol Dial Transplant 1995;20:1228-1230.
63. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acta Radiol 1998;5:491-502.
64. Morcos SK, Thomsen HS, Webb JAW, et al. Dialysis and contrast media. Eur Radiol 2002;12:3026-3030.